Increased Urine IgM and IgG2 Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes
Table 3
Diabetic patients with normoalbuminuria: effects of treatment on urinary indices.
Dalteparin
Placebo
Baseline
At endpoint
Baseline
At endpoint
U-Albumin (mg/mmol)
0.81 (0.07–2.39)
0.77 (0.06–4.97)
0.81 (0.13–4.09)
0.80 (0.19–6.73)
U-IgG2 (mg/mmol)
0.19 (0–8.14)
0.14 (0–7.79)
0.18 (0.06–2.64)
0.16 (0.01–3.79)
U-IgG4 (mg/mmol)
0.05 (0–7.68)
0.04 (0–1.08)
0.07 (0.02–2.51)
0.06 (0.02–4.63)
U-IgG2/u-IgG4
3.49 (0.04–31)
2.20 (0.37–44.59)
2.38 (0.41–8.58)
2.63 (0.54–18.7)
U-GAG (mg/mmol)
2.43 (0.86–8.65)
2.85 (1.32–8)*#
3.32 (0–6.45)
2.53 (0.93–8.99)
U-IgM (mg/mmol)
0.02 (0–0.06)
0.02 (0–0.05)
0.02 (0–0.05)
0.02 (0–0.05)
TGF-β1 (mg/mmol)
3.2 (1.1–379)
5.17 (1.47–21.3)
3.4 (1.4–24.6)
3.32 (1.7–28.9)
GFR (mL/min)
70 (34–190)
65 (33–163)
99 (17–218)
86 (20–334)
()
()
()
()
IGFBP-1 (μg/L)
42 (21–310)
49 (27–315)
38 (15–98)
53 (15–97)
Data are given as the median (with minimum and maximum values in parentheses) of the ratio between urinary concentrations of substance and u-creatinine. * versus placebo; # versus baseline. GFR: glomerular filtration rate: creatinine clearance.
